Workflow
创新医疗器械发展
icon
Search documents
国家药监局党组成员、副局长徐景和在重庆调研医疗器械监管工作
Di Yi Cai Jing· 2025-11-18 09:35
Core Viewpoint - The National Medical Products Administration (NMPA) emphasizes the importance of enhancing the quality and safety supervision of medical devices while promoting innovation in the industry [1] Group 1: Industry Development - The NMPA acknowledges the recent development of the medical device industry in Chongqing and the effectiveness of quality safety supervision [1] - There is a call for a more robust quality safety responsibility system for medical devices, focusing on the entire product lifecycle [1] Group 2: Regulatory Framework - The NMPA stresses the need to strengthen regulatory mechanisms to ensure safety standards are upheld [1] - The agency aims to support the development of innovative medical devices to foster high-quality industrial growth [1]
医疗ETF(159828)涨超1.5%,政策支持或促行业估值修复
Mei Ri Jing Ji Xin Wen· 2025-07-29 04:13
Group 1 - The pharmaceutical and biotechnology sector has shown strong performance recently, particularly in the medical services and medical devices sub-sectors [1] - The National Healthcare Security Administration (NHSA) has held two meetings to support innovative drugs and medical devices, indicating a commitment to integrating high-level technological innovations into clinical practice and promoting the globalization of Chinese medical products [1] - Since June 2025, the regulatory framework for high-end medical devices has been increasingly supportive of innovation, with a focus on "genuine support for innovation, supporting true innovation, and supporting differentiated innovation" [1] Group 2 - The NHSA emphasized that the selection process for centralized procurement will no longer simply reference the lowest price, suggesting that orderly competition will dominate the industry, potentially enhancing profitability and valuation levels in the medical device sector [1] - The current price-to-earnings (PE) ratio for the pharmaceutical and biotechnology sector is 30.67, which is at the historical median level, while the medical device sub-sector has a PE ratio of 32.91, indicating a significant upward trend in the industry under the new policy environment [1]